Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lithium Americas Corp (LAC) vs Novo Nordisk A/S (NVO) Price & Performance

Lithium Americas CorpTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Lithium Americas Corp vs Novo Nordisk A/S — how do they compare? Lithium Americas Corp trades at $3.31 (market cap $1.18B), while Novo Nordisk A/S trades at $46.39 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 176.1× Lithium Americas Corp's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.

LACNVO
Market Cap
$1.18B$207.85B
Sector
Basic MaterialsHealth
52-Week High
$10.05$63.98
52-Week Low
$2.71$35.29
Enterprise Value
$1.29B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lithium Americas Corp

Lithium Americas (LAC) trades at $3.26, showing modest daily gains of 0.31%. The stock exhibits a bullish technical signal with mixed quarterly earnings performance, beating estimates twice but missing significantly in Q4 2025. Recent $175 million financing strengthens the balance sheet as Thacker Pass approaches peak construction. The company maintains negative profitability metrics with ROE at -11.35% but trades below book value at P/B of 0.88.

Investment outlook remains speculative with significant execution risk at Thacker Pass requiring substantial capital expenditures. Analyst consensus leans cautious with 47% buy ratings versus 53% holds. Positive catalysts include lithium demand growth and government support, but cash burn and dilution risks persist for equity holders amid ongoing development phase.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO